ANI Pharma (ANIP) Tops Q4 EPS Views; Issues FY15 Outlook

ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $1.94, $1.36 better than the analyst estimate of $0.58. Revenue for the quarter came in at $21 million versus the consensus estimate of $17.98 million.

ANI Pharma sees FY2015 EPS of $2.48-$2.72, versus the consensus of $2.67. ANI Pharma sees FY2015 revenue of $80-88 million, versus the consensus of $91.6 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• NVE Corporation names new CEO and expands board to seven members
• Jefferies Reinstates Talen Energy (TLN) at Hold